Immunohistochemical expression of PRAME in 485 cases of
epithelial tubo-ovarian tumors

J 2023

Immunohistochemical expression of PRAME in 485 cases of epithelial tubo-ovarian tumors

SAFANDA, Adam, Michaela KENDALL BARTU, Romana MICHALKOVA, Ivana STRUZINSKA, Jana DROZENOVA et. al.

Basic information

Original name

Immunohistochemical expression of PRAME in 485 cases of epithelial tubo-ovarian tumors

Authors

SAFANDA, Adam (203 Czech Republic), Michaela KENDALL BARTU (203 Czech Republic), Romana MICHALKOVA (203 Czech Republic), Ivana STRUZINSKA (203 Czech Republic), Jana DROZENOVA (203 Czech Republic), Pavel FABIAN (203 Czech Republic), Jitka HAUSNEROVÁ (203 Czech Republic, belonging to the institution), Jan LACO (203 Czech Republic), Radoslav MATEJ (203 Czech Republic), Petr SKAPA (203 Czech Republic), Marian SVAJDLER (203 Czech Republic), Zuzana SPURKOVA (203 Czech Republic), Gabor MEHES (203 Czech Republic), Pavel DUNDR (203 Czech Republic) and Kristyna NEMEJCOVA (203 Czech Republic)

Edition

Virchows Archiv, New York, Springer, 2023, 0945-6317

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30109 Pathology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 3.500 in 2022

RIV identification code

RIV/00216224:14110/23:00133230

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1007/s00428-023-03629-z

UT WoS

001063398000003

Keywords in English

PRAME; Immunohistochemistry; Ovarian tumors; Cancer

Abstract

V originále

Preferentially expressed antigen of melanoma (PRAME) is a cancer/testis antigen selectively expressed in somatic tissues and various solid malignant tumors and is associated with poor prognostic outcome. Our research aimed to comprehensively compare its expression in a large cohort of tubo-ovarian epithelial tumors and examine its correlation with our clinico-pathologic data, as well as to assess its potential use in diagnostics and therapy.We examined 485 cases of epithelial tubo-ovarian tumors including 107 clear cell carcinomas (CCC), 52 endometroid carcinomas (EC), 103 high grade serous carcinomas (HGSC), 119 low grade serous carcinomas (LGSC)/micropapillary variant of serous borderline tumors (mSBT), and 104 cases of mucinous carcinomas (MC)/mucinous borderline tumors (MBT). The immunohistochemical analysis was performed using TMAs.The highest levels of expression were seen in EC (60%), HGSC (62%), and CCC (56%), while expression in LGSC/mSBT (4%) and MC/MBT (2%) was rare. The clinico-pathologic correlations and survival analysis showed no prognostic significance.The results of our study showed that PRAME is neither prognostic nor a suitable ancillary marker in the differential diagnosis of tubo-ovarian epithelial tumors. Nevertheless, knowledge about the PRAME expression may be important concerning its potential predictive significance, because targeting PRAME as a potential therapeutic option is currently under investigation.

Links

90233, large research infrastructures

Name: BBMRI.cz IV

Citovat

SAFANDA, Adam, Michaela KENDALL BARTU, Romana MICHALKOVA, Ivana STRUZINSKA, Jana DROZENOVA, Pavel FABIAN, Jitka HAUSNEROVÁ, Jan LACO, Radoslav MATEJ, Petr SKAPA, Marian SVAJDLER, Zuzana SPURKOVA, Gabor MEHES, Pavel DUNDR and Kristyna NEMEJCOVA. Immunohistochemical expression of PRAME in 485 cases of epithelial tubo-ovarian tumors. Virchows Archiv. New York: Springer, 2023, vol. 483, No 4, p. 509-516. ISSN 0945-6317. Available from: https://dx.doi.org/10.1007/s00428-023-03629-z.

@article{2365649,
   author = {Safanda, Adam and Kendall Bartu, Michaela and Michalkova, Romana and Struzinska, Ivana and Drozenova, Jana and Fabian, Pavel and Hausnerová, Jitka and Laco, Jan and Matej, Radoslav and Skapa, Petr and Svajdler, Marian and Spurkova, Zuzana and Mehes, Gabor and Dundr, Pavel and Nemejcova, Kristyna},
   article_location = {New York},
   article_number = {4},
   doi = {http://dx.doi.org/10.1007/s00428-023-03629-z},
   keywords = {PRAME; Immunohistochemistry; Ovarian tumors; Cancer},
   language = {eng},
   issn = {0945-6317},
   journal = {Virchows Archiv},
   title = {Immunohistochemical expression of PRAME in 485 cases of epithelial tubo-ovarian tumors},
   url = {https://link.springer.com/article/10.1007/s00428-023-03629-z},
   volume = {483},
   year = {2023}
}

TY  - JOUR
ID  - 2365649
AU  - Safanda, Adam - Kendall Bartu, Michaela - Michalkova, Romana - Struzinska, Ivana - Drozenova, Jana - Fabian, Pavel - Hausnerová, Jitka - Laco, Jan - Matej, Radoslav - Skapa, Petr - Svajdler, Marian - Spurkova, Zuzana - Mehes, Gabor - Dundr, Pavel - Nemejcova, Kristyna
PY  - 2023
TI  - Immunohistochemical expression of PRAME in 485 cases of epithelial tubo-ovarian tumors
JF  - Virchows Archiv
VL  - 483
IS  - 4
SP  - 509-516
EP  - 509-516
PB  - Springer
SN  - 09456317
KW  - PRAME
KW  - Immunohistochemistry
KW  - Ovarian tumors
KW  - Cancer
UR  - https://link.springer.com/article/10.1007/s00428-023-03629-z
N2  - Preferentially expressed antigen of melanoma (PRAME) is a cancer/testis antigen selectively expressed in somatic tissues and various solid malignant tumors and is associated with poor prognostic outcome. Our research aimed to comprehensively compare its expression in a large cohort of tubo-ovarian epithelial tumors and examine its correlation with our clinico-pathologic data, as well as to assess its potential use in diagnostics and therapy.We examined 485 cases of epithelial tubo-ovarian tumors including 107 clear cell carcinomas (CCC), 52 endometroid carcinomas (EC), 103 high grade serous carcinomas (HGSC), 119 low grade serous carcinomas (LGSC)/micropapillary variant of serous borderline tumors (mSBT), and 104 cases of mucinous carcinomas (MC)/mucinous borderline tumors (MBT). The immunohistochemical analysis was performed using TMAs.The highest levels of expression were seen in EC (60%), HGSC (62%), and CCC (56%), while expression in LGSC/mSBT (4%) and MC/MBT (2%) was rare. The clinico-pathologic correlations and survival analysis showed no prognostic significance.The results of our study showed that PRAME is neither prognostic nor a suitable ancillary marker in the differential diagnosis of tubo-ovarian epithelial tumors. Nevertheless, knowledge about the PRAME expression may be important concerning its potential predictive significance, because targeting PRAME as a potential therapeutic option is currently under investigation.
ER  -

SAFANDA, Adam, Michaela KENDALL BARTU, Romana MICHALKOVA, Ivana STRUZINSKA, Jana DROZENOVA, Pavel FABIAN, Jitka HAUSNEROVÁ, Jan LACO, Radoslav MATEJ, Petr SKAPA, Marian SVAJDLER, Zuzana SPURKOVA, Gabor MEHES, Pavel DUNDR and Kristyna NEMEJCOVA. Immunohistochemical expression of PRAME in 485 cases of epithelial tubo-ovarian tumors. \textit{Virchows Archiv}. New York: Springer, 2023, vol.~483, No~4, p.~509-516. ISSN~0945-6317. Available from: https://dx.doi.org/10.1007/s00428-023-03629-z.

Detailed Information on Publication Record